hCG Trigger Injections in Fertility Treatment

Primary Indications

• The American Society for Reproductive Medicine recommends hCG trigger injections primarily for timing ovulation in intrauterine insemination (IUI) cycles with ovarian stimulation and for inducing final oocyte maturation in IVF/ICSI cycles when the dominant follicle(s) reach approximately 18 mm mean diameter 1, 2
• hCG injections are most commonly used to trigger ovulation in IUI cycles with ovarian stimulation when the dominant follicle reaches a mean diameter of approximately 18 mm, with no evidence to recommend for or against a specific method over alternatives like LH testing or GnRH agonists 1, 2
• When hCG injection is used, single IUI can be performed any time between 24 and 40 hours after hCG injection without compromising pregnancy rates 1, 2

IVF/ICSI Cycles

• The standard approach involves administering hCG when follicles reach appropriate size to trigger final oocyte maturation before retrieval, with a mean time to ovulation of 40.4 hours after intramuscular hCG 3

Male Hypogonadotropic Hypogonadism

• The American Urological Association indicates hCG for selected cases of hypogonadotropic hypogonadism in males, and clinicians may use hCG, aromatase inhibitors, selective estrogen receptor modulators (SERMs), or combinations for infertile men with low serum testosterone 4
• For men interested in current or future fertility, testosterone monotherapy should not be prescribed as it suppresses spermatogenesis 4

Timing Considerations

• In IUI cycles, the 24-40 hour window after hCG provides flexibility without compromising pregnancy rates 1, 2
• In IUI natural cycles, providers can determine the method of timing as there is no evidence to recommend for or against hCG versus LH testing, and IUI should be performed 1 day after LH rise rather than using hCG trigger 1, 2

Evidence‑Based Monitoring and Special‑Population Strategies for hCG Trigger in IVF

Monitoring Parameters

• Serial transvaginal ultrasounds combined with serum hormone assays are used to track follicular development throughout the approximately two‑week course of follicle‑stimulating hormone (FSH) ovarian stimulation. 5

Special Populations

Hormone‑Sensitive Tumors

• In women with estrogen‑sensitive cancers, concurrent administration of aromatase inhibitors (e.g., letrozole) or selective estrogen receptor modulators (e.g., tamoxifen) with FSH reduces systemic estrogen exposure, and short‑term breast‑cancer recurrence rates are comparable to those observed in non‑randomized control groups. 5

Fertility Preservation in Cancer Patients

• For patients requiring urgent fertility preservation, priming with either hCG or a GnRH agonist before in‑vitro maturation (IVM) cycles does not significantly alter oocyte maturation outcomes, indicating that both priming strategies are clinically acceptable. 6

Follicle Monitoring and hCG Trigger Guidelines During Ovarian Stimulation

Monitoring Frequency and Ultrasound Modalities

• Perform transvaginal ultrasound examinations every 2–3 days throughout the roughly two‑week course of FSH ovarian stimulation to track follicular development in all patients undergoing assisted reproduction. 7

Hormonal Monitoring

• Combine serial transvaginal ultrasound findings with serum estradiol (E2) measurements every 2–3 days to assess ovarian response adequately and to predict hyperstimulation risk. [7][8]

hCG Trigger Criteria

Timing and Dosage

• Administer 5,000–10,000 IU hCG intramuscularly when at least three follicles reach a mean diameter ≥ 17 mm and serum E2 is showing an appropriate rise, indicating sufficient follicular maturity. [8][9]

Expected Ovulation Window

• After intramuscular hCG, the mean time to ovulation is approximately 40.4 hours; oocyte retrieval is optimally performed 36–38 hours post‑trigger. 9

Size Thresholds for IVF Cycles

• In in‑vitro fertilisation cycles, the trigger should be given when ≥ 3 follicles are ≥ 17 mm to ensure adequate oocyte maturity. 8

Protocol Selection Based on Ovarian Reserve

Normal Responders

• Use routine ovarian stimulation protocols with a GnRH‑antagonist as first‑line therapy to obtain sufficient embryos for selection and transfer. 9

High Responders

• Prefer GnRH‑antagonist protocols to reduce the risk of ovarian hyperstimulation syndrome while maintaining efficacy. 9
• Implement a “freeze‑all” embryo strategy in fresh cycles when trophectoderm biopsy is performed at the blastocyst stage. 9

Poor Responders

• Consider alternative approaches such as natural‑cycle retrieval, minimal ovarian stimulation, or luteal‑phase stimulation when standard protocols yield inadequate response. 9
• Counsel patients about the possibility of low oocyte numbers, lack of transferable embryos, or complete cycle failure before proceeding with unconventional protocols. 9

Special Population Considerations

BRCA Mutation Carriers

• Exercise particular caution with ovarian stimulation regimens because hormonal exposure may increase cancer risk in this group. 9
• Coordinate assisted reproductive technology and genetic testing timelines with planned risk‑reducing surgeries (e.g., prophylactic mastectomy or oophorectomy). 9

Common Pitfalls to Avoid

• Do not rely solely on ultrasound without concurrent estradiol monitoring; combined assessment provides superior prediction of ovarian response and hyperstimulation risk. [7][8]
• Avoid triggering when fewer than three follicles are ≥ 17 mm, as this diminishes oocyte yield and overall cycle success. 8